Member Info for Bella6532

Manifesto.. If you want to sell quickly in the US you do a deal with a local contract manufacturer/national distributor. Some contract manufacturers have own agents/distributor networks already in place. We were an agent/distributor for likes of Alcan, Ciba Geigy, Pfizer Pigments etc and covered 8 SE states. Anything Covid will be in huge demand and no problem getting players on board and sales teams motivated. Re FDA we already know SNG are working with a company who helped with trial set up and they also assist with regulators including FDA...just need to speed up the pen pushers and to get them to prioritise their work loads... Its also holiday time in Europe and US... Again a point of slowdown... Fat chance getting anything done here in France in August when it comes to Govt bodies... Well shuttered...

We distributed... Grr.

Persimmon... Having lived and worked in the US for many years I would agree they are inward looking but there again it's a huge country and they will always look towards home grown first. Back in my day there their regulators and systems were far more advanced than over in the UK. They were easy to deal with and in general uniform across the country if it was a National approvals body. We did tributes chemicals many of which were extremely volitile. I don't think the current administration is out to block overseas companies but more to cut some of the red tape within the admin side and first come first served mentality. When l listened to the interview link posted with Oxford Prof who new our founder but couldn't remember our company name, it was quite clear scientists around the world are talking to each other more and not waiting to see the final published data. They line everyone want answers and quickly and if picking up the phone or conferencing with zoom then good... And I think this is what the admin is pushing the FDA to do... Pick up the phone don't write endless letters... Speed up the process of info/data collecting and don't process dead beats... Sift through incoming and prioritise the most viable...

16 July and 21 July...

The last time we had a 0%dsy was 21 July 2020...
For those who belive in signalling and/or manipulation, check out RNSs back then.
Have a great weekend all.. See you bright and early on Monday...

It doesn't state when threshold was crossed and most eve ings this week we've seen slugs of late after hours trades put through. My guess is we might get another holding notice from him next week...too much hard work and late volume just for 400K...

Chrishar... They've been loading up all week but not letting on until close of day when after hours trades at put thru. If a tasty RNS is lodged aroundd lunchtime for Monday am release you might see an afternoon uplift but that's not normally how it works with this share/SNG..

Haha... Not a k in sight this morning.. So far!!!

Chimers. Sorry

Chimeras.. Sounds like you're hinting mm manipulation... But we know that never happens!.. lol

Looks like simple stock transfer taking place... Has news been delayed to facilitate?
No TR1???
This is not normal trading... Just look at all those late 19 Aug trades which popped up last night...

What a load of twaddle....

Well well...the late after hours are in including a slug from yesterday too...
They have been working this haven't they...

If an individual or company has an account with a couple of brokers and gives them an oder to each buy a certain amount of SNG shares. At what point does said person/company have to report their holding crossing a threshold... When they actually pay for the shares if they are purchased on account???

Reports like that are purely algorithm driven... Don't fall for them...

Pure algorithm driven...

Page 2
'Synairgen will continue to offer services on a ‘fees for services’ basis to pharmaceutical companies
in order to increase the Group’s profile and initiate commercial relationships which may lead to
collaboration agreements. Whilst these activities are not intended to generate substantial revenues,
they offer an opportunity for the Group to reduce its net cash outflows.
3. Competition
Synairgen competes in the respiratory drug discovery market place with academic units,
biotechnology and pharmaceutical companies around the world. Some academic institutions are
capable of performing facets of research similar to the Group.
Job: 12912K-- Date: 18-10-04 Area: A1 Operator: MC Typesetter ID: DESIGN: ID Number: 1048 TCP No. 7 Time: 20:52 Rev: 1 Gal: 0015
15
Although many pharmaceutical companies are engaged in the development of new pharmaceutical
products, they are increasingly dependent on in-licensed products to fill their pipelines. It is forecast
that by 2007, 40 per cent. of the revenues of the largest twenty pharmaceutical companies will be
generated by in-licensed products. Although these companies are therefore competitors, they also
represent potential collaborators with Synairgen.
Other biotechnology and pharmaceutical companies are involved in respiratory drug development.
However, the Directors are not aware of any company, with the exception of Aerovance, Inc., a
recent spin-out from Bayer, which is solely focused on respiratory drug discovery for asthma and
COPD.
4. Proprietary programmes and collaboration agreements
Key milestones
Synairgen was founded in June 2003 and has already:
established two proprietary programmes for asthma, IFNß for inhalation and Growth
Factor;
entered into two agreements with North American companies (Merck Frosst Canada & Co
and a major US biotechnology company) and one in the UK (Cambridge Antibody
Technology Limited), two of which are IP-sharing collaborations and one of which is a ‘fees
for services’ agreement; and
entered into discussions regarding further collaborations.'

https://www.synairgen.com/wp-content/uploads/2018/06/synairgen-final-admission-document.pdf

The following is not new but nevertheless spells out the companies strategy....
'One of Synairgen’s principal strengths is its proven ability to interpret scientific findings in their
clinical context because of the clinical trials experience of Professor Holgate and Dr Djukanovic.
The collaborative business model
Synairgen pursues the discovery and exploitation of new pharmaceutical products by conducting
its own proprietary research programmes and through collaboration agreements with
pharmaceutical companies.
The Group adopts a collaborative business model whereby it works in partnership with established
pharmaceutical and biotechnology companies on promising research programmes within its areas
of interest. Within this model, collaborations can occur in two ways:
(i) pharmaceutical or biotechnology companies seek Synairgen’s research expertise in
programmes that they have under development; or
(ii) Synairgen seeks partners for its research programmes either from the outset, or once
Synairgen has developed early proof of concept data (“proprietary programmes”).
Under a collaboration agreement, the Directors expect that Synairgen will typically receive fee
income and be entitled to a share of the IP created (typically 50 per cent.), which Synairgen
anticipates would ultimately be licensed under a royalty-bearing deal.
The Group conducts its own proprietary research programmes where the Directors believe that
value will be added to the IP at an early stage in the programme. By conducting a limited number of
proprietary programmes, the Directors believe the Group will be able to enhance its future revenue
prospects due to higher milestones and/or upfront payments and royalties, whilst ensuring a
balanced risk portfolio having regard to the Group’s future capital requirements.
The Group’s strategy is to undertake a portfolio of proprietary and collaborative programmes in its
core areas of focus.
Early out-licensing
The Directors intend to out-license Synairgen’s intellectual property at an early stage of the drug
discovery and development process, which they believe offers significant revenue opportunities.
In the period 2000 to 2002, licensing deals made prior to the commencement of pre-clinical trials
(“Early Stage”) accounted for approximately 68 per cent. of the licensing deals undertaken by the
largest twenty pharmaceutical companies worldwide and amounted to approximately US$5.9
billion. The average upfront payment alone for each of these transactions was approximately
US$5.1 million.
Flexible and low cost operating model
The Directors intend to minimise fixed costs within the business, outsourcing those activities in the
drug discovery and development process not within the Group’s core skill set.'
Cont....

Very very surprised no TR1 yet from our US shareholders... Does this mean others buying or have they been moving more out of holding company over to their other companies or ???

Tad off 248...insert big grin here...